👾Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy 👾Japan Ministry of Hea Saturday September 23rd, 2017By Tokio X'press JPN, Pharmaceutical, USA Bristol-Myers Squibb 👾Japan Ministry of Hea
🎗CELLULAR DYNAMICS INTERNATIONAL SIGNS AGREEMENT WITH NANION TECHNOLOGIES TO ENHANCE MUTUAL OFFERINGS FOR RESEARCHERS . 🎗CELLULAR DYNAMICS INT Thursday September 21st, 2017By Tokio X'press JPN, Pharmaceutical Fujifilm USA 🎗CELLULAR DYNAMICS INT
👾Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan News Release 👾Opdivo® (Nivolumab) I Thursday September 21st, 2017By Tokio X'press JPN, TAI, Pharmaceutical ONO 👾Opdivo® (Nivolumab) I
Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea 20170919 Opdivo® (Nivolumab) Intravenou Tuesday September 19th, 2017By Tokio X'press JPN, Pharmaceutical ONO Opdivo® (Nivolumab) Intravenou
MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies MD Anderson and Daiichi Sankyo Friday September 15th, 2017By Tokio X'press JPN, Pharmaceutical, USA daiichisankyo MD Anderson and Daiichi Sankyo
